ClinicalTrials.gg
CompletedNCT06897202VESPER-2Updated Jun 12, 2026

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

A Phase 2 interventional study of MET097 Injection and Placebo in Obesity in Diabetes and Type 2 Diabetes Mellitus (T2DM), sponsored by Pfizer. Completed at 29 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Diabetes Mellitus, Type 2 by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus, Type 2 · Pfizer.

Enrollment
22nd of 79
133 · median 50
Started
2025
the only one that year
Phase 2
18 of 80
none open now
Registered
77th of 80
by date

Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 22nd largest by enrollment of the 79 interventional ones that give a count, is the only one that started in 2025, is one of 18 in phase 2, and was the 77th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 80 studies in Diabetes Mellitus, Type 2 by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Diabetes Mellitus, Type 2 by Pfizer, or all of them as a file.
02

Study summary

This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.

Read the detailed description

This is a 28-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy, safety, and tolerability of four different once-weekly MET097 dosing regimens vs. placebo for body weight loss in adults (18-75 years of age) with obesity or overweight (body mass index [BMI] ≥27 to ≤50 kg/m2) and T2DM . After completing 28 weeks of study treatment, all participants will be followed for approximately 11 weeks after administration of the last dose of study treatment.

03

Conditions studied

  • Obesity in Diabetes
  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • GLP-1
  • Metsera
  • T2DM
  • Obesity
  • Overweight
  • Weight Loss
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥27.0 kg/m2 to ≤50.0 kg/m2 at screening
  • Type 2 diabetes mellitus (*T2DM) for at least 3 months before screening
  • (HbA1c) value between ≥7.0% (53.0 mmol/mol) and ≤10.5% (91.3 mmol/mol) at Screening and treated with stable therapy for at least 30 days prior to Screening/Visit 1 (diet and exercise alone or in combination with metformin monotherapy and/or SGLT-2)
  • Stable body weight (increase or decrease ≤5 kg) within 3 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Female who is lactating or who is pregnant
  • Estimated (eGFR) \<60 mL/min/1.73 m2
  • Fasting triglycerides ≥ 5.6 mmol/L (≥500 mg/dL)
  • Poorly controlled hypertension
  • History of stroke
  • Significant cardiovascular disease including but not limited to unstable angina or valvular heart disease or has a history of myocardial infarction, coronary artery bypass graft, percutaneous coronary artery re-vascularization, or congestive heart failure
  • Diagnosis of Type 1 diabetes (history of ketoacidosis, hyperosmolar state/coma, or any other types of diabetes except T2DM)
  • History of acute or chronic pancreatitis
  • Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
  • Relevant surgical history including all bariatric or weight loss surgeries
  • SGLT2 inhibitors and/or metformin
  • Had 1 or more episodes of hypoglycemia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    MET097 Active with titration

    Drug: MET097 Injection

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    MET097 Active without titration

    Drug: MET097 Injection

Interventions

  • MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.

  • DrugPlacebo

    Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in body weight at Week 28 (Day 197)

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

Secondary outcomes

  1. Weight reduction (weight loss) from baseline that is ≥ 5%

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

  2. Weight reduction (weight loss) from baseline that is ≥ 10%

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

  3. Weight reduction (weight loss) from baseline that is ≥ 15%

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

  4. Change in glycated hemoglobin A1c (HbA1c)

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

  5. Change from baseline in fasting plasma glucose (FPG)

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

  6. Change from baseline in fasting serum insulin

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

  7. Change from baseline in C-peptide

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

  8. Occurrence of HbA1c <7.0% (53.0 mmol/mol)

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

  9. Occurrence of HbA1c ≤6.5% (47.5 mmol/mol)

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

  10. Occurrence of HbA1c <5.7% (38.8 mmol/mol)

    Time frame: Baseline (Week 0) through Week 28 (Day 197)

  11. Occurrence of treatment-emergent adverse events (TEAEs)

    Treatment emergent adverse events include adverse events of clinical interest as well as abnormal clinical significant physical exams, laboratory findings, and 12-lead ECG measurements that meet the definition for an AE.

    Time frame: Baseline (Week 0) through Week 39 (Day 274)

  12. Occurrence of hypoglycemia according to American Diabetes Association classifications [ADA 2024]

    Time frame: Baseline (Week 0) through Week 39 (Day 274)

  13. Occurrence of anti-drug antibodies

    Time frame: Baseline (Week 0) through Week 39 (Day 274)

  14. Change from baseline in serum albumin

    Time frame: Baseline (Week 0) through Week 39 (Day 274)

  15. Change from baseline in transthyretin [pre-albumin]

    Time frame: Baseline (Week 0) through Week 39 (Day 274)

  16. Change from baseline in high-sensitivity C-reactive Protein [hsCRP]

    Time frame: Baseline (Week 0) through Week 39 (Day 274)

  17. Characterize the minimum observed concentration (Cmin)

    Time frame: Baseline (Week 0) through Week 39 (Day 274)

  18. Characterize the maximum observed concentration (Cmax)

    Time frame: Baseline (Week 0) through Week 39 (Day 274)

  19. Characterize the area under the concentration versus time curve (AUC)

    Time frame: Baseline (Week 0) through Week 39 (Day 274)

  20. Characterize the time to maximum concentration (Tmax)

    Time frame: Baseline (Week 0) through Week 39 (Day 274)

07

Study locations

29 sites
  • KUR Research
    Bessemer, Alabama 35022, United States
  • ProSciento, Inc.
    Chula Vista, California 91911, United States
  • Michael Roberts Opthamologist (Eye Exam)
    Glendale, California 91204, United States
  • Eye Treatment Center
    Long Beach, California 90807, United States
  • Collaborative Neuroscience Research, LLC
    Los Alamitos, California 90720, United States
  • Velocity Clinical Research, Los Angeles
    Los Angeles, California 90017, United States
  • Clinical Innovations, Inc dba CITrials
    Riverside, California 92506, United States
  • Synergy Healthcare
    Bradenton, Florida 34209, United States
  • Miami Eye Institute
    Hollywood, Florida 33024, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
  • EmVenio Research Centre at PRIME Healthcare
    Riverdale, Georgia 30274, United States
  • CenExel iResearch, LLC
    Savannah, Georgia 31405, United States
  • Koch Family Medicine Clinical Research
    Morton, Illinois 61550, United States
  • Bioluminux Clinical Research
    Naperville, Illinois 60540, United States
  • EmVenio Research Centre at PRIME Healthcare
    Kansas City, Kansas 66112, United States
  • Eagle Eye Care
    Columbia, Maryland 21045, United States
  • KUR Research, LLC
    Columbia, Maryland 21045, United States
  • CBH Health, LLC.
    Gaithersburg, Maryland 20877, United States
  • Emvenio Research
    Garden City, Michigan 48135, United States
  • Velocity Clinical Research
    Omaha, Nebraska 68134, United States
  • Advocare Berlin Medical Associates
    Berlin, New Jersey 08009, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • Onsite Clinical Solutions, LLC (Satellite site)
    Charlotte, North Carolina 28277, United States
  • Onsite Clinical Solutions, LLC
    Charlotte, North Carolina 28277, United States
  • EmVenio Research Centre at PRIME Healthcare
    Farmers Branch, Texas 75234, United States
  • Research Your Health
    Plano, Texas 75093, United States
  • Revival Research Institute, LLC
    Sherman, Texas 75092, United States
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Dec 2025, 9 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Mar 26, 2025
StartActual
Mar 14, 2025
Primary completionActual
Dec 29, 2025
CompletionActual
Mar 18, 2026
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06897202
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Mar 14, 2025
Primary completion
Dec 29, 2025
Completion
Mar 18, 2026
Last update
Jun 12, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berobenatide

Start the discussion